期刊文献+

硼替佐米联合阿糖胞苷协同诱导U937细胞凋亡机制的深入研究 被引量:1

Mechanism of Apoptosis Synergistically Induced by Bortezomib Combined with Cytarabine in U937 Cell Line
下载PDF
导出
摘要 本研究旨在探讨蛋白酶体抑制剂硼替佐米联合低浓度阿糖胞苷协同诱导U937细胞凋亡的机制。通过细胞计数检测细胞增殖,用流式细胞仪分析细胞周期和活性氧(ROS)水平,Western blot检测凋亡信号通路相关蛋白的表达。结果表明,10 nmol/L硼替佐米联合50 nmol/L阿糖胞苷对U937细胞有明显增殖抑制作用。两药联合协同诱导细胞凋亡。两药联合较单药处理能明显协同增加U937细胞ROS的水平,并能明显上调U937细胞中p-P38,p-JNK表达,下调p-ERK的表达。结论:硼替佐米联合阿糖胞苷协同诱导U937细胞凋亡,其机制可能与ROS的损伤导致JNK、P38通路的激活和ERK的下调,从而影响细胞线粒体途径有关。 This study was aimed to further explore the apoptosis-inducing effect of bortezomib combined with cytarabine (Ara-C) on U937 cell line. Proliferation and apoptosis in U937 cells treated with bortezomib and/or Ara-C were assessed by cell count. Cell cycle distribution and reactive oxygen species (ROS) production level were measured by using flow cytometry. Cell signaling pathway related to apoptosis was analyzed by Western blot. The results showed that 10 nmol/L bortezomib combined with 50 nmol/L Ara-C significantly inhibited U937 cell proliferation. These two drug combination synergistically induced apoptosis in U937 cells, significantly increased cellular ROS level, and up- regulated the expression of phosphorylated form of JNK and P38 and down-regulated phosphorylation of ERK. It is concluded that the apoptosis of U937 cells synergistically induced by bortezomib combined with low concentration Ara-C is possibly associated with up-regulation of phosphorylated form of JNK, P38 and down-regulation of phosphorylation of ERK induced by increase of ROS, resulting in decrease of mitochrondrial potential.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2012年第6期1356-1360,共5页 Journal of Experimental Hematology
基金 上海市科委基金(编号10411966900) 国家自然科学基金(编号30971275) 上海市优秀学术带头人计划(编号11XB1403500) JRC杨森科学委员会基金
关键词 硼替佐米 阿糖胞苷 U937细胞 凋亡 bortezomib cytarabine U937 cells apoptosis
  • 相关文献

参考文献23

  • 1Kane RC, Bross PF, Farrell AT, et al. Velcade: U. S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist, 2003 ; 8 ( 6 ) :508 - 513.
  • 2Boccadoro M,Morgan G, Cavenagh J, et al. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int,2005 ;5 ( 1 ) : 18 - 27.
  • 3Roussel M, Facon T, Moreau P, et al. Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. Recent Results Cancer Res,2011 ; 183 : 189 - 206.
  • 4Chang JE, Kahl BS. Current status of targeted therapies for mantle cell lymphoma. Drugs, 2011 ;71 (17) :2307 - 2326.
  • 5Riccioni R, Senese M,Diverio D, et al. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. Br J Hemato1,2007 ; 139 (2) : 194 - 205.
  • 6Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004; 10 (10) :3371 -3376.
  • 7杜欣,贾培敏,何丛,杜圣红,童建华,周励.硼替佐米联合低浓度阿糖胞苷诱导U937细胞凋亡的研究[J].中国实验血液学杂志,2012,20(3):554-557. 被引量:1
  • 8Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncology, 2005 ; 23 ( 3 ) :630 - 639.
  • 9Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK-and NF-kappbB- dependent process. Oncogene, 2003 ;22(46) :7108 -7122.
  • 10Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. P Natl Acad Sci USA, 2002 ;99(25 ) :16220- 16225.

二级参考文献14

  • 1Kane RC, Bross PF, Farrell AT, et al. Velcade: U. S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oneologist,2003 ;8 (6) :508 - 513.
  • 2Boccadoro M, Morgan G,Cavenagh J, et al. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int ,2005 ;5 ( 1 ) : 18 - 27.
  • 3Roussel M, Facon T, Moreau P, et al. Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. Recent Results Cancer Res,2011 ;183:189 -206.
  • 4Chang JE, Kahl BS. Current status of targeted therapies for mantle cell lymphoma. Drugs, 2011 ;71 ( 17 ) :2307 - 2326.
  • 5Sehn LH, MacDonald D, Rubin S, et al. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol,2011 ;29 (25) :3396 - 3401.
  • 6Fowler N, Kahl BS,Lee P, et al. Bortezomib,bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol, 2011 ; 29 (25) :3389 - 3395.
  • 7Ravandi F. New treatments and strategies in acute myeloid Leukemia. Clin Lymphoma Myeloma Leuk,2011 ;11 ( Suppl 1 ) : $60 - 64.
  • 8Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther,2009 ;31 (2) :2349 -2370.
  • 9Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Onco1,2005 ;23 (3) :630 - 639.
  • 10Kumatori A, Tanaka K, Inamura N, et al. Abnormally high expression of proteasomes in human leukemic cells. PNAS, 1990;87 (18) :7071 -7075.

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部